MeMed's Sepsis Severity Test Gains FDA Breakthrough Device Designation
核心洞察
MeMed (搜索)'s Severity test received FDA Breakthrough Device designation to improve management of suspected acute infections (搜索) and sepsis (搜索).
The test uses host-response technology and machine learning to stratify patients' risk of severe outcomes or death.
Results are available in under 15 minutes, integrating into clinical workflows for triage, treatment, and discharge decisions.
MeMed (搜索) has been granted Breakthrough Device designation (BDD) from the U.S. Food and Drug Administration (FDA) for its MeMed Severity test (搜索), a diagnostic tool designed to improve the management of patients with suspected acute infections (搜索) and sepsis (搜索). The test leverages host-response technology to measure proteins in blood samples, employing machine learning algorithms to stratify a patient's risk of severe outcomes or death within a specified timeframe.
This rapid risk stratification capability complements clinical assessments and other laboratory findings, providing clinicians with valuable insights for patient management. MeMed (搜索) Severity builds upon the foundation of the FDA-cleared MeMed BV test (搜索), which aids clinicians in distinguishing between bacterial and viral infections.
Designed for Emergency Department Use
The MeMed Severity test (搜索) is tailored for use in emergency departments, supporting critical decisions regarding patient triage, treatment strategies, and disposition. It assists clinicians in determining which patients require escalated care and those who can be safely discharged, potentially optimizing resource allocation and improving patient outcomes.
With results available in less than 15 minutes, the test's compatibility with high-throughput analyzers, quick turnaround time, and minimal blood volume requirements are designed to seamlessly integrate into existing clinical workflows. This rapid availability of results can facilitate timely interventions and improve patient management.
CEO's Vision and FDA Collaboration
MeMed (搜索) CEO and co-founder Eran Eden stated, "Our vision is to revolutionize diagnostics and improve patient outcomes globally. The FDA's BDD for MeMed Severity validates our commitment to addressing critical healthcare challenges with novel host-response technologies." He also expressed gratitude for the FDA's collaboration during the test's development process, emphasizing its potential to fill a critical gap in sepsis (搜索) management and improve care.
The Breakthrough Device designation not only expedites the test's market introduction but also facilitates the establishment of reimbursement strategies. While MeMed (搜索) Severity has not yet received approval for sale by any regulatory authority, this designation marks a significant step toward its potential clinical use.
In July 2023, MeMed (搜索) BV was cleared by the FDA and received a CE marking under the European In Vitro Diagnostic Devices Regulation (IVDR) in the EU, further expanding the company's diagnostic capabilities.